[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX351273B - Nuevo anticuerpo anti-ngf humano. - Google Patents

Nuevo anticuerpo anti-ngf humano.

Info

Publication number
MX351273B
MX351273B MX2014001627A MX2014001627A MX351273B MX 351273 B MX351273 B MX 351273B MX 2014001627 A MX2014001627 A MX 2014001627A MX 2014001627 A MX2014001627 A MX 2014001627A MX 351273 B MX351273 B MX 351273B
Authority
MX
Mexico
Prior art keywords
human ngf
ngf antibody
antibody
antigen
seq
Prior art date
Application number
MX2014001627A
Other languages
English (en)
Other versions
MX2014001627A (es
Inventor
Kamohara Masazumi
Tanaka Hirotsugu
Koya Yukari
Takasaki Jun
Yonezawa Atsuo
Yoshimi Eiji
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2014001627A publication Critical patent/MX2014001627A/es
Publication of MX351273B publication Critical patent/MX351273B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-NGF humano o un fragmento de unión al antígeno del mismo que es excelente en seguridad al reducir el riesgo de efectos secundarios como los efectos en una formación del feto y del trombo mientras que mantiene una actividad de neutralización alta, y proporciona los medios para prevenir o para tratar varias enfermedades en las cuales el NGF humano está implicado en la formación de las condiciones patológicas, usando el anticuerpo o el fragmento de unión al anticuerpo del mismo. El fragmento Fab' del anticuerpo anti-NGF humano comprende una región variable de cadena pesada que consiste en una secuencia de aminoácido mostrada por la SEC ID NO: 6 y una región variable de cadena ligera que consiste en una secuencia de aminoácido mostrada por la SEC ID NO: 4.
MX2014001627A 2011-08-11 2012-08-10 Nuevo anticuerpo anti-ngf humano. MX351273B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011176209 2011-08-11
JP2011269215 2011-12-08
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトｎｇｆ抗体

Publications (2)

Publication Number Publication Date
MX2014001627A MX2014001627A (es) 2014-05-28
MX351273B true MX351273B (es) 2017-10-06

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001627A MX351273B (es) 2011-08-11 2012-08-10 Nuevo anticuerpo anti-ngf humano.

Country Status (28)

Country Link
US (2) US8986952B2 (es)
EP (1) EP2743348B1 (es)
JP (1) JP5376095B2 (es)
KR (1) KR101999867B1 (es)
CN (1) CN103748222B (es)
AR (1) AR087506A1 (es)
AU (1) AU2012293161B2 (es)
BR (1) BR112014002576B1 (es)
CA (1) CA2841181C (es)
CY (1) CY1119914T1 (es)
DK (1) DK2743348T3 (es)
EA (1) EA024292B1 (es)
ES (1) ES2663968T3 (es)
HR (1) HRP20180155T1 (es)
HU (1) HUE036079T2 (es)
IL (1) IL230797A (es)
IN (1) IN2014CN00614A (es)
LT (1) LT2743348T (es)
ME (1) ME02944B (es)
MX (1) MX351273B (es)
NO (1) NO2743348T3 (es)
PL (1) PL2743348T3 (es)
PT (1) PT2743348T (es)
RS (1) RS56876B1 (es)
SI (1) SI2743348T1 (es)
TW (1) TWI554519B (es)
WO (1) WO2013022083A1 (es)
ZA (1) ZA201400741B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
JP6700620B2 (ja) * 2015-05-22 2020-05-27 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
EP3434283A4 (en) * 2016-03-25 2019-11-13 Astellas Pharma Inc. MEDICINAL COMPOSITION CONTAINING FAB 'FRAGMENT OF ANTI-NGF PEG HUMAN ANTIBODIES
CN109929035B (zh) * 2017-12-15 2022-06-28 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
WO2019221097A1 (ja) 2018-05-15 2019-11-21 アステラス製薬株式会社 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
KR100337069B1 (ko) 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101653604A (zh) 2001-05-30 2010-02-24 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
NZ540730A (en) 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
SI1648509T1 (sl) 2003-07-15 2012-12-31 Amgen Inc. Humana protitelesa, ki nevtralizirajo anti-ngf, kot selektivni inhibitorji poti nfg
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CN101107268B (zh) 2005-01-24 2012-06-27 剑桥抗体技术有限公司 针对ngf的特异性结合成员
WO2009023540A1 (en) * 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
ES2498065T3 (es) 2007-10-24 2014-09-24 Astellas Pharma Inc. Compuesto de azolcarboxamida o sal del mismo
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Also Published As

Publication number Publication date
US8986952B2 (en) 2015-03-24
JP5376095B2 (ja) 2013-12-25
IL230797A0 (en) 2014-03-31
NO2743348T3 (es) 2018-06-09
KR101999867B1 (ko) 2019-07-12
RS56876B1 (sr) 2018-04-30
JPWO2013022083A1 (ja) 2015-03-05
ME02944B (me) 2018-04-20
TW201319086A (zh) 2013-05-16
ES2663968T3 (es) 2018-04-17
CY1119914T1 (el) 2018-06-27
CA2841181A1 (en) 2013-02-14
LT2743348T (lt) 2018-05-10
AR087506A1 (es) 2014-03-26
US20150218265A1 (en) 2015-08-06
CN103748222A (zh) 2014-04-23
HRP20180155T1 (hr) 2018-03-23
BR112014002576A2 (pt) 2021-01-12
CN103748222B (zh) 2015-07-22
TWI554519B (zh) 2016-10-21
PL2743348T3 (pl) 2018-04-30
IL230797A (en) 2017-06-29
EP2743348A1 (en) 2014-06-18
EP2743348B1 (en) 2018-01-10
AU2012293161B2 (en) 2017-04-27
EA201490433A1 (ru) 2014-05-30
US20140155582A1 (en) 2014-06-05
EA024292B1 (ru) 2016-09-30
AU2012293161A1 (en) 2014-02-06
MX2014001627A (es) 2014-05-28
WO2013022083A1 (ja) 2013-02-14
HUE036079T2 (hu) 2018-06-28
ZA201400741B (en) 2014-11-26
KR20140047116A (ko) 2014-04-21
PT2743348T (pt) 2018-02-23
IN2014CN00614A (es) 2015-04-03
DK2743348T3 (en) 2018-02-26
CA2841181C (en) 2022-01-25
EP2743348A4 (en) 2015-04-29
BR112014002576B1 (pt) 2022-08-23
SI2743348T1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
MX2014001627A (es) Nuevo anticuerpo anti-ngf humano.
MX2014001371A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
NZ714516A (en) Human antibodies to clostridium difficile toxins
NZ706986A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
MX2014001370A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
HRP20171992T1 (hr) Protutijela protiv cgrp
EA033400B1 (ru) Антитело против cd3 и его применение
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
PH12019501104A1 (en) Novel anti-human muc1 antibody fab fragment
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
PE20170687A1 (es) Proteinas de enlace a cd127
BR112018006579A2 (pt) anticorpos anti-humanos cd19 humanizados e métodos de uso
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
EP2581113A4 (en) ANTI-TIM-3 ANTIBODIES
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
NZ706377A (en) Il-6 antagonists and uses thereof
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
WO2013188870A3 (en) IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
NZ609607A (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
CO2022008204A2 (es) Anticuerpos biparatópicos frente a cd73
MX345019B (es) Nuevo anticuerpo ctgf antihumano.
PH12017502126A1 (en) Novel anti-human ngf antibody fab fragment
JP2014515743A5 (es)
SG10201903424RA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
NZ627024A (en) Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient

Legal Events

Date Code Title Description
FG Grant or registration